Browsing Tag
Biologics
20 posts
Tezspire gains FDA approval for CRSwNP, expanding AstraZeneca and Amgen’s reach in inflammatory airway diseases
Tezspire gets FDA approval for chronic rhinosinusitis with nasal polyps. See how AstraZeneca and Amgen are expanding the respiratory biologics frontier.
Amgen and AstraZeneca win FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Find out how Amgen and AstraZeneca’s Tezspire approval for nasal polyps redefines biologic therapy and reshapes investor confidence today.
Why Leo Pharma’s completed Spevigo deal with Boehringer could reshape rare skin disease care
Leo Pharma completes its acquisition of Spevigo® from Boehringer Ingelheim. Learn how this rare disease drug strengthens its dermatology growth strategy.
Absci goes full throttle on AI drug design with Oracle and AMD in its corner
Absci taps Oracle Cloud and AMD’s Instinct GPUs to fast-track AI-powered drug discovery and antibody design. Find out what this means for biotech’s future.
Will NASP transform gout care in 2026? Sobi’s biologic therapy heads for FDA decision
Sobi’s NASP for uncontrolled gout advances to FDA review with June 2026 PDUFA date. Find out how this novel therapy could reshape gout treatment.
Inside Kemin’s animal health push: what the Hennessy Research Associates deal really means for vaccine innovation
Kemin Industries acquires Hennessy Research Associates, adding vaccine R&D and manufacturing expertise. Learn how this deal reshapes the animal health industry.
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.
CSL wins FDA approval for ANDEMBRY, the first monthly anti-factor XIIa therapy for hereditary angioedema
CSL’s ANDEMBRY gains U.S. FDA approval as the first monthly HAE treatment targeting factor XIIa. Learn how it redefines disease control for patients.
OneSource Specialty Pharma reports stellar Q3FY25 earnings with 85% EBITDA growth, setting stage for expansion
OneSource Specialty Pharma Limited, formerly Stelis Biopharma Limited, has delivered a strong financial performance in its first full…